- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2012 (2012), Article ID 568567, 11 pages
Patient-Derived Xenografts of Non Small Cell Lung Cancer: Resurgence of an Old Model for Investigation of Modern Concepts of Tailored Therapy and Cancer Stem Cells
1Tumor Genomics Unit, Department of Experimental Oncology and Molecular Medicine, IRCCS Foundation National Cancer Institute, Via Venezian 1, 20133 Milan, Italy
2Molecular Pharmacology Unit, Department of Experimental Oncology and Molecular Medicine, IRCCS Foundation National Cancer Institute, Via Venezian 1, 20133 Milan, Italy
3Thoracic Surgery Unit, Department of Surgery, IRCCS Foundation National Cancer Institute, Via Venezian 1, 20133 Milan, Italy
Received 28 December 2011; Accepted 10 January 2012
Academic Editor: Andrea Vecchione
Copyright © 2012 Massimo Moro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- D. Decaudin, “Primary human tumor xenografted models (“tumorgrafts”) for good management of patients with cancer,” Anti-Cancer Drugs, vol. 22, no. 9, pp. 827–841, 2011.
- S. Venkatesh and R. A. Lipper, “Role of the development scientist in compound lead selection and optimization,” Journal of Pharmaceutical Sciences, vol. 89, no. 2, pp. 145–154, 2000.
- R. H. Shoemaker, “The NCI60 human tumour cell line anticancer drug screen,” Nature Reviews Cancer, vol. 6, no. 10, pp. 813–823, 2006.
- S. A. Burchill, “What do, can and should we learn from models to evaluate potential anticancer agents?” Future Oncology, vol. 2, no. 2, pp. 201–211, 2006.
- C. A. Carter, C. Chen, C. Brink et al., “Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma,” Cancer Chemotherapy and Pharmacology, vol. 59, no. 2, pp. 183–195, 2007.
- T. Voskoglou-Nomikos, J. L. Pater, and L. Seymour, “Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models,” Clinical Cancer Research, vol. 9, no. 11, pp. 4227–4239, 2003.
- L. Q. M. Chow and S. G. Eckhardt, “Sunitinib: from rational design to clinical efficacy,” Journal of Clinical Oncology, vol. 25, no. 7, pp. 884–896, 2007.
- J. Fogh and B. C. Giovanella, The Nude Mouse in Experimental and Clinical Research, Academic Press, 1978.
- H. Castrop, “Genetically modified mice-successes and failures of a widely used technology,” Pflugers Archiv European Journal of Physiology, vol. 459, no. 4, pp. 557–567, 2010.
- D. J. Wells, “Genetically modified animals and pharmacological research,” Handbook of Experimental Pharmacology, vol. 199, pp. 213–226, 2010.
- M. A. G. Sosa, R. De Gasperi, and G. A. Elder, “Animal transgenesis: an overview,” Brain Structure and Function, vol. 214, no. 2-3, pp. 91–109, 2010.
- J. W. Gordon, G. A. Scangos, and D. J. Plotkin, “Genetic transformation of mouse embryos by microinjection of purified DNA,” Proceedings of the National Academy of Sciences of the United States of America, vol. 77, no. 12, pp. 7380–7384, 1980.
- K. R. Thomas and M. R. Capecchi, “Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells,” Cell, vol. 51, no. 3, pp. 503–512, 1987.
- J. H. Lin, “Applications and limitations of genetically modified mouse models in drug discovery and development,” Current Drug Metabolism, vol. 9, no. 5, pp. 419–438, 2008.
- B. Bolon, “Genetically engineered animals in drug discovery and development: a maturing resource for toxicologic research,” Basic and Clinical Pharmacology and Toxicology, vol. 95, no. 4, pp. 154–161, 2004.
- R. Clarke, “Animal models of breast cancer: experimental design and their use in nutrition and psychosocial research,” Breast Cancer Research and Treatment, vol. 46, no. 2-3, pp. 117–133, 1997.
- J. K. Peterson and P. J. Houghton, “Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development,” European Journal of Cancer, vol. 40, no. 6, pp. 837–844, 2004.
- B. Firestone, “The challenge of selecting the “right” in vivo oncology pharmacology model,” Current Opinion in Pharmacology, vol. 10, no. 4, pp. 391–396, 2010.
- J. Rygaard and C. O. Povlsen, “Heterotransplantation of a human malignant tumour to “Nude” mice,” Acta Pathologica et Microbiologica Scandinavica, vol. 77, no. 4, pp. 758–760, 1969.
- B. C. Giovanella, S. O. Yim, J. S. Stehlin, and L. J. Williams, “Development of invasive tumors in the “nude” mouse after injection of cultured human melanoma cells,” Journal of the National Cancer Institute, vol. 48, no. 5, pp. 1531–1533, 1972.
- B. C. Giovanella, D. M. Vardeman, L. J. Williams et al., “Heterotransplantation of human breast carcinomas in nude mice. Correlation between successful heterotransplants, poor prognosis and amplification of the HER-2/neu oncogene,” International Journal of Cancer, vol. 47, no. 1, pp. 66–71, 1991.
- V. C. Daniel, L. Marchionni, J. S. Hierman et al., “A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro,” Cancer Research, vol. 69, no. 8, pp. 3364–3373, 2009.
- R. S. Kerbel, “Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved,” Cancer biology & therapy, vol. 2, no. 4, pp. S134–S139, 2003.
- J. I. Johnson, S. Decker, D. Zaharevitz et al., “Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials,” British Journal of Cancer, vol. 84, no. 10, pp. 1424–1431, 2001.
- C. C. Scholz, D. P. Berger, B. R. Winterhalter, H. Henss, and H. H. Fiebig, “Correlation of drug response in patients and in the clonogenic assay with solid human tumour xenografts,” European Journal of Cancer, vol. 26, no. 8, pp. 901–905, 1990.
- M. Hidalgo, E. Bruckheimer, N. V. Rajeshkumar et al., “A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer,” Molecular Cancer Therapeutics, vol. 10, no. 8, pp. 1311–1316, 2011.
- A. Bertotti, G. Migliardi, F. Galimi, et al., “A molecularly annotated platform of patient-derived xenografts (“Xenopatient”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer,” Cancer Discovery, vol. 1, no. 6, pp. 508–523, 2011.
- R. Krumbach, J. Schüler, M. Hofmann, T. Giesemann, H. -H. Fiebig, and T. Beckers, “Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance,” European Journal of Cancer, vol. 47, no. 8, pp. 1231–1243, 2011.
- S. Sun, J. H. Schiller, and A. F. Gazdar, “Lung cancer in never smokers—a different disease,” Nature Reviews Cancer, vol. 7, no. 10, pp. 778–790, 2007.
- A. Spira, J. Beane, V. Shah et al., “Effects of cigarette smoke on the human airway epithelial cell transcriptome,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 27, pp. 10143–10148, 2004.
- J. Plowman, D. J. Dykes, M. Hollingshead, L. Simpson-Herren, and M. C. Alley, “Human tumor xenograft models in NCI drug development,” in Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials and Approval, B. Teicher, Ed., pp. 101–125, Humana Press, Totowa, NJ, 1997.
- T. John, D. Kohler, M. Pintilie et al., “The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer,” Clinical Cancer Research, vol. 17, no. 1, pp. 134–141, 2011.
- G. Bertolini, L. Roz, P. Perego et al., “Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 38, pp. 16281–16286, 2009.
- I. Fichtner, J. Rolff, R. Soong et al., “Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers,” Clinical Cancer Research, vol. 14, no. 20, pp. 6456–6468, 2008.
- S. Hammer, A. Sommer, I. Fichtner et al., “Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer,” Clinical Cancer Research, vol. 16, no. 5, pp. 1452–1465, 2010.
- X. Dong, J. Guan, J. C. English et al., “Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy,” Clinical Cancer Research, vol. 16, no. 5, pp. 1442–1451, 2010.
- E. Marangoni, A. Vincent-Salomon, N. Auger et al., “A new model of patient tumor-derived breast cancer xenografts for preclinical assays,” Clinical Cancer Research, vol. 13, no. 13, pp. 3989–3998, 2007.
- L. De Plater, A. Laugé, C. Guyader et al., “Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation,” British Journal of Cancer, vol. 103, no. 8, pp. 1192–1200, 2010.
- M. R. Simpson-Abelson, G. F. Sonnenberg, H. Takita et al., “Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rγnull Mice,” Journal of Immunology, vol. 180, no. 10, pp. 7009–7018, 2008.
- T. Reya, S. J. Morrison, M. F. Clarke, and I. L. Weissman, “Stem cells, cancer, and cancer stem cells,” Nature, vol. 414, no. 6859, pp. 105–111, 2001.
- R. Pardal, M. F. Clarke, and S. J. Morrison, “Applying the principles of stem-cell biology to cancer,” Nature Reviews Cancer, vol. 3, no. 12, pp. 895–902, 2003.
- M. F. Clarke, “Self-renewal and solid-tumor stem cells,” Biology of Blood and Marrow Transplantation, vol. 11, no. 2, pp. 14–16, 2005.
- M. F. Clarke, J. E. Dick, P. B. Dirks et al., “Cancer stem cells—perspectives on current status and future directions: AACR workshop on cancer stem cells,” Cancer Research, vol. 66, no. 19, pp. 9339–9344, 2006.
- D. Bonnet and J. E. Dick, “Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell,” Nature Medicine, vol. 3, no. 7, pp. 730–737, 1997.
- S. K. Singh, I. D. Clarke, M. Terasaki et al., “Identification of a cancer stem cell in human brain tumors,” Cancer Research, vol. 63, no. 18, pp. 5821–5828, 2003.
- H. D. Hemmati, I. Nakano, J. A. Lazareff et al., “Cancerous stem cells can arise from pediatric brain tumors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 25, pp. 15178–15183, 2003.
- R. Galli, E. Binda, U. Orfanelli et al., “Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma,” Cancer Research, vol. 64, no. 19, pp. 7011–7021, 2004.
- D. Fang, T. K. Nguyen, K. Leishear et al., “A tumorigenic subpopulation with stem cell properties in melanomas,” Cancer Research, vol. 65, no. 20, pp. 9328–9337, 2005.
- T. Schatton, G. F. Murphy, N. Y. Frank et al., “Identification of cells initiating human melanomas,” Nature, vol. 451, no. 7176, pp. 345–349, 2008.
- M. Al-Hajj, M. S. Wicha, A. Benito-Hernandez, S. J. Morrison, and M. F. Clarke, “Prospective identification of tumorigenic breast cancer cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 7, pp. 3983–3988, 2003.
- S. A. Bapat, A. M. Mali, C. B. Koppikar, and N. K. Kurrey, “Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer,” Cancer Research, vol. 65, no. 8, pp. 3025–3029, 2005.
- A. T. Collins, P. A. Berry, C. Hyde, M. J. Stower, and N. J. Maitland, “Prospective identification of tumorigenic prostate cancer stem cells,” Cancer Research, vol. 65, no. 23, pp. 10946–10951, 2005.
- L. Ricci-Vitiani, D. G. Lombardi, E. Pilozzi et al., “Identification and expansion of human colon-cancer-initiating cells,” Nature, vol. 445, no. 7123, pp. 111–115, 2007.
- C. A. O'Brien, A. Pollett, S. Gallinger, and J. E. Dick, “A human colon cancer cell capable of initiating tumour growth in immunodeficient mice,” Nature, vol. 445, no. 7123, pp. 106–110, 2007.
- P. Dalerba, S. J. Dylla, I. K. Park et al., “Phenotypic characterization of human colorectal cancer stem cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 24, pp. 10158–10163, 2007.
- A. Eramo, F. Lotti, G. Sette et al., “Identification and expansion of the tumorigenic lung cancer stem cell population,” Cell Death and Differentiation, vol. 15, no. 3, pp. 504–514, 2008.
- G. Bertolini, L. Gatti, and L. Roz, “The “stem” of chemoresistance,” Cell Cycle, vol. 9, no. 4, pp. 628–629, 2010.
- A. Jimeno, G. Feldmann, A. Suárez-Gauthier et al., “A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development,” Molecular Cancer Therapeutics, vol. 8, no. 2, pp. 310–314, 2009.
- T. Hoey, W. C. Yen, F. Axelrod et al., “DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency,” Cell Stem Cell, vol. 5, no. 2, pp. 168–177, 2009.
- C. Ginestier, S. Liu, M. E. Diebel et al., “CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts,” Journal of Clinical Investigation, vol. 120, no. 2, pp. 485–497, 2010.
- S. J. Dylla, L. Beviglia, I. K. Park et al., “Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy,” PLoS One, vol. 3, no. 6, Article ID e2428, 2008.
- Z. A. Rasheed, J. Yang, Q. Wang et al., “Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma,” Journal of the National Cancer Institute, vol. 102, no. 5, pp. 340–351, 2010.
- M. P. Kim, J. B. Fleming, H. Wang et al., “ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma,” PLoS One, vol. 6, no. 6, Article ID e20636, 2011.
- P. Workman, E. O. Aboagye, F. Balkwill et al., “Guidelines for the welfare and use of animals in cancer research,” British Journal of Cancer, vol. 102, no. 11, pp. 1555–1577, 2010.